Overview

The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD).

Eligibility

Inclusion Criteria:

        Twenty patients with histologically proven treatment-naïve, therapy-refractory or relapsed
        blood cancers meeting the below criteria will be included:
          -  Indolent B- or T-cell Non-Hodgkin lymphoma (including cutaneous lymphomas) or
             Non-Hodgkin lymphoma with variable FDG uptake and clinical course, such as mantle cell
             lymphoma; and measurable disease according to Lugano criteria
        or
          -  Histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease
             (ECD) and/or Rosai-Dorfman disease (RDD)
          -  MGUS/SMM or MM according to IMWG definitions
          -  Age ≥18
          -  Negative serum pregnancy test for female volunteers of childbearing age and potential
             (as defined by MSKCC Standards & Guidelines) from assays obtained <2 weeks prior to
             study enrollment/intervention; or negative urine pregnancy test performed on the day
             of intervention
          -  MSKCC patients
        Exclusion Criteria:
          -  Breast-feeding
          -  History of renal functional disorders (chronic kidney disease with eGFR<30)
          -  Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)